Delving into the Latest Updates on Pharm Sintez with Synapse

概览

疾病领域	数量

神经系统疾病	1

排名前五的药物类型	数量

诊断用放射药物	1
小分子化药	1
化学药	1
生物药	1

关联

4

项与 Pharm Sintez 相关的药物

Cellex

靶点-

作用机制-

在研机构

Pharm Sintez

原研机构

Pharm Sintez

在研适应症

脑血管疾病

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

俄罗斯

首次获批日期2011-01-01

Rezoskan-99mTc(Pharm-Sintez)

靶点-

作用机制

SPECT

在研机构

Pharm Sintez

原研机构

Pharm Sintez

在研适应症

诊断试剂

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

俄罗斯

首次获批日期2009-04-22

Thiozonide

靶点-

作用机制-

在研机构

Pharm Sintez

原研机构

Pharm Sintez

在研适应症-

非在研适应症-

最高研发阶段临床阶段不明

首次获批国家/地区-

首次获批日期-

100 项与 Pharm Sintez 相关的临床结果

登录后查看更多信息

0 项与 Pharm Sintez 相关的专利（医药）

登录后查看更多信息

5

项与 Pharm Sintez 相关的文献（医药）

2014-05-01·Chemistry of Heterocyclic Compounds

One-Step Facile Synthesis of L-Proline Ethylamide Hydrochloride

作者: V. E. Fedorov ; A. N. Balaev ; K. A. Okmanovich ; V. N. Osipov

The title compound was prepared by a Me₂SiCl₂-mediated amidation of L-proline on an >100 g scale, and pure N-ethyl-L-prolinamide.HCl was isolated without any column chromatog.Furthermore, a preliminary study on the reaction of L-proline with other amines revealed that the corresponding amides can be prepared in yields ≤80%.

2009-06-01·Monatshefte für Chemie - Chemical Monthly

Synthesis of imatinib: a convergent approach revisited

作者: Sergey V. Shishkov ; Andrey S. Ivanov

A classical convergent approach for the synthesis of the anticancer drug imatinib has been substantially improved.Imatinib was assembled by coupling the amine and carboxylic acid precursors by using N,N'-carbonyldiimidazole (CDI) as a condensing agent.Both intermediates have been synthesized by novel efficient methods.

Journal Biomed

Comprehensive Assessment of the Safety of a New Antituberculosis Drug from the Diarylquinolines Group

作者: Burenkov, M. S. ; Savchenko, A. Yu. ; Kukes, V. G. ; Ramenskaya, G. V. ; Shilov, B. V.

The safety of the new anti-tuberculosis drug Tiozonide was studied by bioinformatics and preclinical methods using laboratory animals and with the participation of healthy volunteers. The absence of toxic effects on the main life support systems of mammals predicted by QSAR models was confi rmed by the results of acute, subchronic and chronic toxicity tests in various laboratory animals. Monitoring of the vital indicators of volunteers and a comparative analysis of the generalized results of these indicators before (screening), during and after the study showed the absence of reliable and clinically signifi cant changes that threaten the life and health of people.

100 项与 Pharm Sintez 相关的药物交易

登录后查看更多信息

100 项与 Pharm Sintez 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年01月04日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

2

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Rezoskan-99mTc(Pharm-Sintez)	诊断试剂更多	批准上市
Cellex	脑血管疾病更多	批准上市
Thiozonide	-	临床阶段不明
ZoleRen	肿瘤更多	无进展